本文關(guān)鍵詞： 生物制藥行業(yè) 經(jīng)營(yíng)績(jī)效 BCC模型 Malmquist生產(chǎn)率指數(shù)　出處：《江西師范大學(xué)》2014年碩士論文　論文類型：學(xué)位論文

【摘要】：生物制藥行業(yè)在國(guó)內(nèi)處于非常有利的的發(fā)展條件。首先，對(duì)生物制藥行業(yè)發(fā)展政策形成有利的支持。生物制藥行業(yè)易受政策影響，積極有力的政策環(huán)境能夠推動(dòng)行業(yè)的迅速發(fā)展。其次，醫(yī)療衛(wèi)生水平幫助提高生物制藥行業(yè)的健康、穩(wěn)定的發(fā)展水平。隨著我國(guó)國(guó)民經(jīng)濟(jì)的快速發(fā)展以及醫(yī)療衛(wèi)生水平不斷提高，越來(lái)越多的人能夠消費(fèi)起價(jià)格相對(duì)較高的生物藥品。然而，，我國(guó)生物制藥行業(yè)存在諸多問(wèn)題，如研發(fā)資金投入比重不足、科研創(chuàng)新能力薄弱、科技成果轉(zhuǎn)化率低和產(chǎn)能過(guò)剩競(jìng)爭(zhēng)過(guò)度等問(wèn)題。在此背景下，評(píng)價(jià)我國(guó)生物制藥行業(yè)的經(jīng)營(yíng)績(jī)效，有利于促進(jìn)該行業(yè)穩(wěn)定健康以及提升其競(jìng)爭(zhēng)力。 文章采用BCC模型以及基于DEA模型的Malmquist生產(chǎn)率指數(shù)的方法對(duì)我國(guó)生物制藥行業(yè)經(jīng)營(yíng)的績(jī)效進(jìn)行評(píng)估。選取長(zhǎng)春高新、雙鷺?biāo)帢I(yè)等25家主營(yíng)生物藥品的上市公司作為樣本。以證監(jiān)會(huì)行業(yè)標(biāo)準(zhǔn)劃分為基礎(chǔ)，這25家上市公司包括有12家屬于生物制品業(yè)，12家屬于生物藥品制造業(yè)，1家屬于其他生物制品業(yè)。本文采用總資產(chǎn)、主營(yíng)業(yè)務(wù)成本和各項(xiàng)費(fèi)用作為投入指標(biāo)，凈利潤(rùn)和主營(yíng)業(yè)務(wù)收入作為產(chǎn)出指標(biāo)。 在本文中，采用BCC模型對(duì)我國(guó)25家生物制藥行業(yè)主要上市公司2008—2012年間的經(jīng)營(yíng)績(jī)效進(jìn)行評(píng)價(jià)，并結(jié)合了Malmquist生產(chǎn)率指數(shù)，對(duì)樣本期間內(nèi)生物制藥行業(yè)上市公司經(jīng)營(yíng)績(jī)效變換進(jìn)行了動(dòng)態(tài)評(píng)價(jià)。研究結(jié)果顯示：第一，采用靜態(tài)評(píng)價(jià)得到的結(jié)果是規(guī)模效率明顯偏低，樣本期間內(nèi)我國(guó)生物制藥行業(yè)主要上市公司的經(jīng)營(yíng)績(jī)效相對(duì)不高，需要改善；第二，運(yùn)用動(dòng)態(tài)評(píng)價(jià)得出技術(shù)水平下降呈現(xiàn)變化是全要素效率下降的主要原因。 最后，對(duì)本人的研究成果做了總結(jié)，以及基于實(shí)證研究得出的結(jié)論，提出相應(yīng)的對(duì)策建議，以期促進(jìn)生物制藥行業(yè)的穩(wěn)定發(fā)展。
[Abstract]:Biopharmaceutical industry in China is in a very favorable development conditions. First of all, the development of the biopharmaceutical industry policy to form a favorable support. Biopharmaceutical industry is vulnerable to the impact of the policy. An active policy environment can promote the rapid development of the industry. Secondly, the level of health care helps to improve the health of the biopharmaceutical industry. With the rapid development of our national economy and the continuous improvement of medical and health standards, more and more people can consume the relatively high prices of biological drugs. There are many problems in the biopharmaceutical industry in China, such as insufficient proportion of R & D funds, weak ability of scientific research and innovation, low conversion rate of scientific and technological achievements and excessive overcapacity competition. The evaluation of the performance of the biopharmaceutical industry in China is beneficial to promote the stability and health of the industry and enhance its competitiveness. This paper uses BCC model and Malmquist productivity index based on DEA model to evaluate the performance of Chinese biopharmaceutical industry. A sample of 25 listed companies, including Shuanglu Pharmacy, which specializes in biopharmaceuticals. Based on the industry standards of the CSRC, 12 of the 25 listed companies are in the biological products industry. In this paper, total assets, main business costs and various expenses are used as input indicators, while net profit and main business income are taken as output indicators. In this paper, the BCC model is used to evaluate the operating performance of 25 biopharmaceutical companies in China from 2008 to 2012. Combined with the Malmquist productivity index, the dynamic evaluation of the operating performance transformation of the listed companies in the biopharmaceutical industry during the sample period is carried out. The results show that: first. The result of the static evaluation is that the scale efficiency is obviously low, and the operating performance of the main listed companies in the biopharmaceutical industry in China is relatively low during the sample period, which needs to be improved. Secondly, the dynamic evaluation shows that the decline of technical level is the main reason for the decline of total factor efficiency. Finally, this paper summarizes my research results, and based on the conclusions of empirical research, puts forward corresponding countermeasures and suggestions, in order to promote the stable development of the biopharmaceutical industry.
【學(xué)位授予單位】：江西師范大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉玉海;呂坤;;中國(guó)釀酒業(yè)上市公司的效率特征及其影響因素分析——基于DEA-Tobit兩階段模型[J];財(cái)經(jīng)論叢;2010年02期

2 張道峰;馬愛(ài)霞;;基于中國(guó)制藥業(yè)上市公司的綜合績(jī)效評(píng)價(jià)研究[J];經(jīng)營(yíng)管理者;2011年08期

3 吉生保;席艷玲;;中國(guó)食品飲料行業(yè)經(jīng)營(yíng)績(jī)效評(píng)價(jià)及影響因素——基于SORM-BCC和Malmquist的DEA-Tobit模型[J];上海經(jīng)濟(jì)研究;2011年09期

4 錢侃;夏洪勝;;基于DEA模型的通信服務(wù)業(yè)上市公司效率的實(shí)證分析[J];科技管理研究;2011年20期

5 劉建忠;;我國(guó)醫(yī)藥高新技術(shù)產(chǎn)業(yè)科技投入績(jī)效評(píng)價(jià)研究[J];科學(xué)管理研究;2009年02期

6 宋馬林;王舒鴻;汝慧萍;張廷海;;中國(guó)新興生物企業(yè)的生產(chǎn)效率及其不確定性——基于DEA和神經(jīng)網(wǎng)絡(luò)模擬的面板數(shù)據(jù)分析[J];科學(xué)學(xué)與科學(xué)技術(shù)管理;2010年10期

7 尹學(xué)慧;;基于DEA模型的我國(guó)醫(yī)藥上市企業(yè)經(jīng)營(yíng)績(jī)效評(píng)價(jià)[J];商場(chǎng)現(xiàn)代化;2009年13期

8 王蘊(yùn)翠;張小虎;;廣東生物醫(yī)藥產(chǎn)業(yè)競(jìng)爭(zhēng)力評(píng)價(jià)研究——基于DEA模型的分析[J];商場(chǎng)現(xiàn)代化;2010年02期

9 李春頂;;中國(guó)制造業(yè)行業(yè)生產(chǎn)率的變動(dòng)及影響因素——基于DEA技術(shù)的1998～2007年行業(yè)面板數(shù)據(jù)分析[J];數(shù)量經(jīng)濟(jì)技術(shù)經(jīng)濟(jì)研究;2009年12期

10 吉生保;周小柯;趙海斌;;中國(guó)機(jī)械設(shè)備行業(yè)經(jīng)營(yíng)績(jī)效評(píng)價(jià)及影響因素——基于超效率DEA-Tobit模型[J];山西財(cái)經(jīng)大學(xué)學(xué)報(bào);2011年01期

相關(guān)博士學(xué)位論文 前1條

1 王曉東;中國(guó)高科技上市公司經(jīng)營(yíng)效率及其影響因素研究[D];暨南大學(xué);2009年

本文編號(hào)：1484752